All In Biotech

Drug Trial Radar · NCT03013400

Ebselen as an add-on Treatment in Hypo/Mania

A Randomised, Parallel Group, Double Blind, Placebo Controlled, Add on Clinical Trial to Investigate Whether the Lithium Mimetic, Ebselen, Can Reduce Symptoms of Hypomania and Mania in Bipolar Patients

Last checked: Nov 19, 2026Latest source record: Sep 6, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

60

Actual

Start

Oct 1, 2017

Primary completion

Jul 9, 2019

Study completion Jul 9, 2019

Sponsor

Lead sponsor
University of OxfordAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Stanley Medical Research Institute; Sound Pharmaceuticals, Incorporated
First posted
Jan 6, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study evaluates the effect of a 'lithium like' drug called ebselen (SP-1005) versus placebo as an 'add on' treatment to help stabilise hypo/manic symptoms in bipolar disorder. Half of the participants will receive ebselen and the other half placebo. The trial, will last a total of four weeks.

Conditions

  • Bipolar Disorder
  • Bipolar Disorder, Manic

Interventions

  • EbselenDrug

    Ebselen is an opaque capsule containing 200 mg of ebselen is a selenium-based GPx mimic and IMPase inhibitor.

  • Placebo oral capsuleDrug

    Placebo is identical in appearance to the ebselen capsules

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Young Mania Rating Scale (YMRS)Time frame: Change between groups, every week, up to 4 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Neurosciences Building, Dept. Psychiatry, Warneford Hospital

    Oxford, Oxfordshire, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.